Anales de la RANM

60 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 HISTORIA DE LOS FÁRMACOS ANTIARRÍTMICOS Tamargo Menéndez J An RANM. 2025;142(01): 51 - 60 28. Goette A, Corradi D, Dobrev D, et al. Atrial cardiomyopathy revisited-evolution of a con- cept: a clinical consensus statement of the Eu- ropean Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). Europace 2024;26:euae204. 29. Blomström-Lundqvist C, Naccarelli GV, Mc- Kindley DS, Bigot G, Wieloch M, Hohnloser SH. Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial. Europace 2023;25:845–854. 30. Heijman J, Hohnloser SH, Camm AJ. Antiarr- hythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future. Europace 2021;23(Suppl 2):ii14-ii22. 31. Saljic A, Heijman J, Dobrev D. Recent Advan- ces in Antiarrhythmic Drug Therapy. Drugs 2023;83(13):1147-1160. 32. Mondéjar-Parreño G, Sánchez-Pérez P, Cruz FM, Jalife J. Promising tools for future drug discovery and development in antiarrhythmic therapy. Pharmacol Rev 2025;77:10001. 33. Tamargo J, Caballero R, Gómez R, Delpón E. IKur/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin Investig Drugs 2009;18:399-416. 34. Caballero R, de la Fuente MG, Gómez R, et al. In humans, chronic atrial fibrillation decreases the transient outward current and ultrarapid component of the delayed rectifier current di- fferentially on each atria and increases the slow component of the delayed rectifier current in both. J Am Coll Cardiol 2010;55:2346-2354. 35. Reiffel JA, Blomström-Lundqvist C, Boriani G, et al. Real-world utilization of the pill-in- the-pocket method for terminating episodes of atrial fibrillation: data from the multinational Antiarrhythmic Interventions for Managing Atrial Fibrillation (AIM-AF) survey. Europace 2023;25:euad162. 36. Ruskin JN, Camm AJ, Dufton C, et al. Orally inhaled flecainide for conversion of atrial fibri- llation to Sinus rhythm: INSTANT phase 2 trial. JACC Clin Electrophysiol 2024;10:1021–1033. 37. Ip JE, Coutu B, Noseworthy PA, et al. Etripamil Nasal Spray for Recurrent Paroxysmal Supra- ventricular Tachycardia Conversion. J Am Coll Cardiol 2024;83:2032-2034. 38. Roy A, Varela M, Chubb H, et al. Identifying locations of re-entrant drivers from patient- specific distribution of fibrosis in the left atrium. PLoS Comput Biol 2020;16:e1008086. 39. Markman TM, Geng Z, Epstein AE, et al. Trends in antiarrhythmic drug use among pa- tients in the United States between 2004 and 2016. Circulation 2020;141:937–939. 40. Bazan V, Arana E, Rubio-Campal JM, et al. Spanish catheter ablation registry. 23rd official report of the Heart Rhythm Association of the Spanish Society of Cardiology (2023). Rev Esp Cardiol (Engl Ed) 2024;77:1026-1036. 41. Camm AJ, Blomström-Lundqvist C, Boriani G, et al. AIM-AF: A Physician Survey in the United States and Europe. J Am Heart Assoc 2022;11:e023838. Si desea citar nuestro artículo: Tamargo Menéndez J. La historia de los fármacos antiarrítmi- cos: un camino tortuoso marcado por los fracasos. An RANM. 2025;142(01): 51– 60. DOI: 10.32440/ar.2025.142.01. rev05